By Jessica Dye ( October 15, 2010, 10:59 AM EDT) -- A U.S. Food and Drug Administration advisory panel will meet on Monday to evaluate chronic kidney disease patients' use of popular anemia drugs made by Johnson & Johnson and Amgen Inc. and consider possible labeling and dosage changes, in light of new concerns about the drugs' health risks....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.